Latest Schlieren Stories
The vaccine based on Cytos' Virus-Like Particle technology may open the door to accelerated production of influenza vaccines in SingaporeSingapore and Schlieren (Zurich), Switzerland, May 17, 2013 - (ACN Newswire) - Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos'...
SCHLIEREN, Switzerland, February 14, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today presented its full year 2012 financial results. Full year consolidated financial figures 2012: Balance Sheet Funds available for financing the Company's operations amount to CHF 28.70 million as per December 31, 2012, and include cash and cash equivalents, financial assets and trade and other receivables. They were slightly lower than at the end of December...
SCHLIEREN, Switzerland, July 30, 2012 /PRNewswire/ -- - Cytos Biotechnology Ltd substantially increases its cash by raising CHF 33.58 million through equity and debt - Board of Directors further strengthened by the nomination of Dr. Christian Itin, former President and CEO of Micromet Inc., as a Non-Executive Director - Large global Phase IIb program with CYT003 in allergic asthma planned to start in 2H12 Cytos...
SCHLIEREN, Switzerland, March 5 /PRNewswire/ -- - Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, today announced the successful closing of a CHF25 million (ca. US$22 million, EUR17 million) Series B financing. The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the...
